Skip to main content
Sagimet Biosciences Inc. logo

Sagimet Biosciences Inc. — Investor Relations & Filings

Ticker · SGMT ISIN · US7867001049 LEI · 2549002OT2F8BV0VPD02 US Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2025-03-12 Regulatory Filings
Country US United States of America
Listing US SGMT

About Sagimet Biosciences Inc.

https://sagimet.com/

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company that develops novel fatty acid synthase (FASN) inhibitors. These therapeutics are designed to target dysfunctional metabolic and fibrotic pathways resulting from the overproduction of the fatty acid, palmitate. The company's lead product candidate is denifanstat, and its pipeline includes TVB-3567. Sagimet is exploring the application of its FASN inhibitors in treating diseases where dysregulation of fatty acid metabolism plays a key role, such as metabolic dysfunction-associated steatohepatitis (MASH), acne, and select forms of cancer.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 12, 2025, by Sagimet Biosciences Inc. It reports the issuance of a press release announcing financial results for the fourth quarter and year ended December 31, 2024, and an updated investor presentation. The document explicitly states that the press release and presentation are attached as exhibits and incorporated by reference. The text does not contain the actual financial results or detailed financial statements but rather announces their release and provides references to the exhibits. The document length is 4591 characters, which is relatively short and consistent with an announcement rather than a full report. According to the "Menu vs Meal" rule, this is an announcement of a report and presentation, not the reports themselves. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not fit other specific categories like Earnings Release or Investor Presentation directly since it only announces them.
2025-03-12 English
10-K
Annual Report FY 2024
2025-03-12 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text specifically mentions an "Other Events" section describing the clearance of an IND application and includes a press release as an exhibit. There are no financial statements or detailed financial data presented, and the document length is relatively short (3683 characters). The document is not an annual or quarterly report, nor is it a transcript or detailed financial presentation. It is an event-driven regulatory filing reporting a material event. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2025-03-11 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-14 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Sagimet Biosciences Inc. dated February 14, 2025. It references an updated investor presentation attached as Exhibit 99.1. The text indicates that the presentation is used in meetings with investors and is incorporated by reference, but the document itself is a short current report (3,674 characters) announcing this update. There are no financial statements or detailed financial data included in this text. According to the rules, a short document announcing or attaching a presentation is classified as an Investor Presentation (IP) if it contains the presentation itself or as a Regulatory Filing (RNS) if it is just an announcement. Here, the presentation is attached as an exhibit, and the document is the Form 8-K report announcing it. Since the presentation is attached and incorporated, and the document is a Form 8-K, the best classification is Investor Presentation (IP). Confidence is high because the document explicitly states the presentation is attached and used for investor meetings, matching the IP category.
2025-02-14 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-02-07 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.